Why Aren’t There More Treatments for Secondary Progressive MS?
One of the most common and deeply felt frustrations in the MS community is that most treatments are focused on people with relapsing-remitting MS (RRMS), while those living with secondary progressive MS (SPMS) often feel left behind. It’s understandable to feel disappointed, angry, or even hopeless when you hear that a treatment isn’t available for […]
Tolebrutinib – A New Era of MS Treatments Targeting Progression in Non-Relapsing MS
Tolebrutinib is the first and only disease modifying therapy (DMT) showing positive signs of slowing progression in non-relapsing secondary progressive MS (SPMS). While current DMTs focus on dampening the inflammatory aspects of MS, this significant breakthrough heralds a potential new era of therapies which look to target the underlying progression in MS. Currently in NZ, […]
Are you on an Infusion Treatment?
At MSNZ we would like to understand more about patient experiences with infusion treatments. The first line Disease Modifying Treatment (DMT) options we have been successful in advocating for in NZ are considered some of the best in the world. Due to the availability of these treatments and adopting healthy lifestyle recommendations, people are reportedly […]
Update: Siponimod (Mayzent) for Secondary Progressive MS
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the Neurological Advisory Committee regarding appropriate Special Authority criteria. PTAC’s recommendation noted specifically the consideration of […]
Calling all people with Secondary Progressive MS
Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC in August. Siponimod has been shown to have benefits for those with Secondary Progressive MS. […]
ECTRIMS 2021 Conference Review
The 37th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) was held online recently. The scientific programme comprised well-known session formats such as Scientific Sessions, Hot Topics and Meet the Experts, as well as live discussions between the international faculty and participants at the end of each session. Highlights in this […]